BHVN

Biohaven Pharmaceutical Stock Price

62.00
2.34 (3.92%)
Upgrade to Real-Time
Afterhours (Closed)
62.00
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Biohaven Pharmaceutical Holding Company Ltd BHVN NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
2.34 3.92% 62.00 20:00:00
Close Price Low Price High Price Open Price Previous Close
62.00 57.70 62.19 59.71 59.66
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,614 651,846 $ 60.17 $ 39,223,613 469,070 26.56 - 78.75
Last Trade Time Type Quantity Stock Price Currency
19:00:00 21,712 $ 62.00 USD

Biohaven Pharmaceutical Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 3.70B 59.69M 43.68M $ - $ - -10.99 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
9.51M $ - 0.00% -266.94k 9.20%

more financials information »

Biohaven Pharmaceutical News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BHVN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week63.2065.2057.7062.58462,911-1.20-1.9%
1 Month60.9065.2057.7061.87413,5621.101.81%
3 Months68.7778.7557.6666.41499,749-6.77-9.84%
6 Months29.7978.7528.25555.50738,39632.21108.12%
1 Year46.7278.7526.5651.64771,29115.2832.71%
3 Years37.1378.7516.500144.56605,67824.8766.98%
5 Years20.0078.7516.500143.71560,10442.00210.0%

Biohaven Pharmaceutical Description

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.


Your Recent History
NYSE
BHVN
Biohaven P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.